Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57127 | 0.93 | ALDH1A1 (0.35) | ALDH1A1 | |
| Ethylene Glycol SCHEMBL22721956 | 0.81 | EGLN1 (0.38) | ALDH1A1 | |
| SCHEMBL3622179 | 0.78 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL7450423 | 0.77 | — | — | |
| Ethylene Glycol SCHEMBL18076243 | 0.77 | ALDH1A1 (0.44) | ALDH1A1 | |
| Ethylene Glycol SCHEMBL6523934 | 0.76 | TSHR (0.44) | ALDH1A1 | |
| SCHEMBL1705352 | 0.76 | — | — | |
| Ethylene Glycol SCHEMBL21352286 | 0.75 | ALDH1A1 (0.60) | ALDH1A1 | |
| Benzamide SCHEMBL1205193 | 0.74 | L3MBTL1 (0.50) | ALDH1A1 | |
| SCHEMBL43574 | 0.73 | EGLN1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118105543-A | Vancomycin-carrying hydrogel porous surgical implant for treating infectious bone defect and preparation method thereof | 山东大学齐鲁医院 | 2024-05-31 | — | — | CN | claimed |
| US-20240238480-A1 | DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS | TULAVI THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| CN-118105543-A | Vancomycin-carrying hydrogel porous surgical implant for treating infectious bone defect and preparation method thereof | 山东大学齐鲁医院 | 2024-05-31 | — | — | CN | disclosed |
| EP-4370038-A1 | METHODS AND DEVICES FOR NERVE REGENERATION | Tulavi Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11944717-B2 | Devices for in situ formed nerve caps and/or nerve wraps | Tulavi Therapeutics, Inc. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11890393-B2 | Methods and devices for in situ formed nerve cap | Tulavi Therapeutics, Inc. (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2023288218-A1 | METHODS AND DEVICES FOR NERVE REGENERATION | Tulavi Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220409902-A1 | METHODS AND DEVICES FOR NERVE REGENERATION | TULAVI THERAPEUTICS INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220054705-A1 | DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS | Tulavi Therapeutics, Inc. | 2022-02-24 | — | — | US | disclosed |
| US-20210361292-A1 | METHODS FOR IN SITU FORMED NERVE CAP WITH RAPID RELEASE | INCEPT, LLC | 2021-11-25 | — | — | US | disclosed |
| US-20210315587-A1 | METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP WITH RAPID RELEASE | INCEPT, LLC | 2021-10-14 | — | — | US | disclosed |
| WO-2021146330-A1 | METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP WITH RAPID RELEASE | Tulavi Therapeutics, Inc. (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20210205501-A1 | SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION | Tulavi Therapeutics, Inc. | 2021-07-08 | — | — | US | disclosed |
| US-20210187160-A1 | METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP | Tulavi Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| EP-3817786-A1 | METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP | Tulavi Therapeutics, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| EP-3764990-A1 | SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION | Tulavi Therapeutics, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178564-A1 | SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION | Tulavi Therapeutics, Inc. (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-0981548-A4 | SINGLE-CHAIN ANTIGEN-BINDING PROTEINS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF | ENZON INC (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-0981548-A1 | SINGLE-CHAIN ANTIGEN-BINDING PROTEINS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF | ENZON, INC. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998049198-A1 | SINGLE-CHAIN ANTIGEN-BINDING PROTEINS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF | ENZON, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944717-B2 | Devices for in situ formed nerve caps and/or nerve wraps | GAP43, NGF, CAPG | ALDH1A1 3624/4885 |
| US-20240238480-A1 | DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS | GAP43, NGF, CAPG | ALDH1A1 3624/4885 |
| US-11890393-B2 | Methods and devices for in situ formed nerve cap | NGF, GAP43, CAPRIN1 | ALDH1A1 2796/4885 |
| US-20220054705-A1 | DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS | GAP43, NGF, CAPG | ALDH1A1 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.